AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets 10:27:29 28/05/2026 pm IST			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Market Cap	5.84Cr 6.74Cr 5.51Cr 5Cr 9.38Cr 646.1Cr 9.45Cr 66Cr 25Cr 327.76Cr 25Cr 25Cr 1.04TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.84Cr 6.74Cr 5.51Cr 5Cr 9.38Cr 646.1Cr 9.45Cr 66Cr 25Cr 327.76Cr 25Cr 25Cr 1.04TCr	EV / Sales 2026 *	48.7x	EV / Sales 2027 *	44.9x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Share Price OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quarterly revenue - Rate of surprise

24/08	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	3.84
5 years	0	16.74
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	6.78Cr
MERCK & CO., INC.	+0.47%	-2.47%	+78.72%	+33.78%	36TCr
MERCK KGAA	-0.68%	-3.37%	+22.35%	-20.78%	6.63TCr
HALOZYME THERAPEUTICS, INC.	+0.53%	-0.54%	+41.12%	+165.84%	1.22TCr
KYOWA KIRIN CO., LTD.	+1.55%	-7.41%	-9.13%	-17.39%	747.11Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.38%	-8.66%	-28.74%	-9.08%	463.88Cr
YUHAN CORPORATION	-0.38%	-2.83%	-33.92%	+12.39%	441.87Cr
BETTA PHARMACEUTICALS CO., LTD.	+2.59%	-4.57%	-33.92%	-8.21%	285.73Cr
SUPERNUS PHARMACEUTICALS, INC.	+0.52%	-0.82%	-4.34%	+43.72%	242.04Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.37%	-3.70%	-27.42%	-25.72%	190.2Cr
Average	+0.56%	-3.76%	+0.53%	+19.39%	5.08TCr
Weighted average by Cap.	+0.33%	-4.10%	+64.35%	+27.44%

	2026 *	2027 *
Net sales	12L 13.85L 11.32L 10.27L 19.27L 13Cr 19.41L 1.35Cr 52.12L 6.73Cr 52.01L 50.87L 21Cr	13L 15L 12.27L 11.13L 20.88L 14Cr 21.03L 1.47Cr 56.46L 7.29Cr 56.35L 55.11L 23Cr
Net income	-	-
Net Debt	-	-